Feature | February 12, 2013

Novel Radiation Therapy Method Shortens Prostate Cancer Treatment Time

Radiation Therapy Prostate Cancer VMAT IMRT

February 12, 2013 — According to a clinical study in the January issue of the Journal of the American College of Radiology, the use of volume-modulated arc therapy (VMAT) to deliver intensity-modulated radiation therapy (IMRT) to prostate cancer patients results in an overall reduction in treatment time of approximately 14 percent.

Treatment with IMRT is increasingly standard for prostate cancer. However, although the benefits of IMRT in the treatment of prostate cancer are ample, it remains a complex and time-consuming treatment modality that requires numerous gantry positions, a large number of monitor units and considerable daily treatment time commitments by patients.

“Given the time requirement by patients for daily prostate cancer treatment, we aimed to measure the true efficiency of VMAT treatment compared with IMRT using custom institutional software to record the actual in-room times,” said William A. Hall, M.D., author of the study.

Custom institutional software was used to mine the treatment times from the record-and-verify database. The in-room time (the time between patient entry and exit) was computed for each patient. Average room time was compared between VMAT patients and IMRT patients. Subgroup comparisons (1-arc or 2-arc VMAT, 5-field or 7-field IMRT, and electromagnetic transponder [Calypso] or gold-marker tracking) were performed.

Average room time was significantly shorter for all VMAT versus DMLC IMRT procedures. The average room time for all DMLC IMRT patients was found to be 14.69 ± 4.36 min, and the average room time for all VMAT patients was found to be 12.6 ± 2.62 min. Room time was longer for Calypso versus gold seed patients, but VMAT reduced treatment time in Calypso patients. This resulted in Calypso VMAT patients’ having similar treatment times to non-Calypso DMLC IMRT patients.

“With an aging population and rapidly rising rates of prostate cancer, the ability to determine the most efficient modality by which patients with adenocarcinoma of the prostate should be treated is critical. It seems from our analysis that 5-field IMRT and VMAT are the most efficient modalities by which to deliver prostate IMRT,” said Hall. 

“Furthermore, our analysis shows that if more advanced methods of IMRT delivery are used, localization devices can be incorporated without any statistically significant differences in the overall treatment time. This may provide important information to prostate cancer practices looking to improve their efficiency while maximizing the quality of their radiation therapy delivery,” said Hall.

For more information: www.acr.org

Related Content

University Medical Center Groningen Performs First Automatic Log-based Proton Therapy Patient QA
News | Proton Therapy | June 14, 2019
IBA announced the physics team of University Medical Center Groningen (UMCG) in the Netherlands has developed and...
ASTRO Applauds New Prior Authorization Legislation
News | Radiation Therapy | June 07, 2019
The American Society for Radiation Oncology (ASTRO) released a statement applauding Congress’s introduction of...
IBA Dosimetry Launches myQA iON
News | Quality Assurance (QA) | June 07, 2019
IBA (Ion Beam Applications S.A.) announced the launch of myQA iON at the 2019 Particle Therapy Co-Operative Group (...
Study Identifies MRI-Guided Radiation Therapy as Growing Market Segment
News | Image Guided Radiation Therapy (IGRT) | June 06, 2019
Revenues from the magnetic resonance imaging (MRI)-guided radiation therapy systems market exceeded $220 million in...
RefleXion Opens New Manufacturing Facility for Biology-guided Radiotherapy Platform
News | Radiation Therapy | May 31, 2019
RefleXion Medical recently announced the opening of its new manufacturing facility at its headquarters in Hayward,...
AI Biomarker Demonstrates High Predictive Power for Lung Cancer Immunotherapy
News | Artificial Intelligence | May 31, 2019
Lunit announced an abstract presentation of its artificial intelligence (AI) precision medicine research portfolio at...
Dynamic Digital Radiography Used to Assess Undifferentiated Dyspnea
News | Digital Radiography (DR) | May 29, 2019
A clinical study presented at the American Thoracic Society (ATS) 2019 annual meeting, May 17-22 in Dallas, described...
Leica Biosystems Receives FDA Clearance for Aperio AT2 DX Digital Pathology System
Technology | Digital Pathology | May 29, 2019
Leica Biosystems has received clearance from the U.S. Food and Drug Administration (FDA) to market its Aperio AT2 DX...
Accuray Radixact

Accuray Radixact

Feature | Radiation Therapy | May 29, 2019 | By Jeff Zagoudis
While radiation therapy as a disciplin
Sponsored Content | Case Study | Radiation Therapy | May 29, 2019
The so-called “Grey Tsunami” of baby boomers using healthcare services isn’t taking the Radiation Medicine Program at